Search Results - "Dembla, Vikas"

Idiosyncratic Reaction with Cytokine Storm Associated with Oxaliplatin by Dembla, Vikas

“…Oxaliplatin or irinotecan with 5-fluorouracil form the chemotherapy backbone of any systemic treatment of colorectal cancer. We successfully treated an…”
Get full text

A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment by El-Khoueiry, Anthony B., Tchekmedyian, Nishan, Sanborn, Rachel E., Peguero, Julio Antonio, Pulver, Kerry, Dembla, Vikas, Thomas, Jacob Stephen, Chiang, Gary Gene, Densel, Mark, Sankar, Neil, Worland, Stephen Theodore, Gleich, Lyon L., Sikorski, Robert S.

“…Abstract only 3112 Background: Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response…”
Get full text

CodeBreak 100: Phase I study of AMG 510, a novel KRAS G12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) by Hong, David S., Kuo, James, Sacher, Adrian G., Barlesi, Fabrice, Besse, Benjamin, Kuboki, Yasutoshi, Dy, Grace K., Dembla, Vikas, Krauss, John C., Burns, Timothy F., Kim, June, Henary, Haby, Ngarmchamnanrith, Gataree, Li, Bob T.

“…Abstract only 3511 Background: Kirsten rat sarcoma viral oncogene homolog ( KRAS) p.G12C mutation occurs in approximately 13% of NSCLC and 1%–3% of CRC and…”
Get full text

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic by Dembla, Vikas, Somaiah, Neeta, Barata, Pedro, Hess, Kenneth, Fu, Siqing, Janku, Filip, Karp, Daniel D, Naing, Aung, Piha-Paul, Sarina Anne, Subbiah, Vivek, Tsimberidou, Apostolia M, Shaw, Kenna, Meric-Bernstam, Funda, Hong, David S

“…is the most commonly mutated gene in cancer and codes for the best studied tumor suppressor, p53. MDM2 is involved in the negative regulation of p53 and itself…”
Get full text

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors by Dembla, Vikas, Groisberg, Roman, Hess, Ken, Fu, Siqing, Wheler, Jennifer, Hong, David S., Janku, Filip, Zinner, Ralph, Piha-Paul, Sarina Anne, Ravi, Vinod, Benjamin, Robert S., Patel, Shreyaskumar, Somaiah, Neeta, Herzog, Cynthia E., Karp, Daniel D., Roszik, Jason, Meric-Bernstam, Funda, Subbiah, Vivek

“…Pazopanib is US FDA approved for the treatment of advanced soft tissue sarcomas. All patients with this disease ultimately develop resistance to therapy…”
Get full text

Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors by Dembla, Vikas, Fu, Siqing, Wheler, Jennifer, Hong, David S., Janku, Filip, Zinner, Ralph, Piha-Paul, Sarina Anne, Ravi, Vinod, Benjamin, Robert S., Patel, Shreyaskumar, Somaiah, Neeta, Herzog, Cynthia E., Karp, Daniel D., Meric-Bernstam, Funda, Subbiah, Vivek

“…Abstract only…”
Get full text

Cyclosporine dependent pure red cell aplasia: A case presentation by Al-Issa, Karam, Visconte, Valeria, Rogers, Heesun J., Dembla, Vikas, Lichtin, Alan E., Tiu, Ramon V.

Get full text

Hematuria--a rare presentation of Hodgkin lymphoma by Dembla, Vikas, Walker, Brian N, Elkins, Stephanie L, Files, Joe C

Get full text

Idiosyncratic Reaction with Cytokine Storm Associated with Oxaliplatin by Dembla, Vikas

Get full text